Market Place
Sourcing Support
OrsoBio Announces Data on Novel Approach fo Metabolic Dysfunction
15 Oct 2024 //
BUSINESSWIRE
OrsoBio Raises $67M For Mitochondrial Protonophore Obesity Portfolio
06 Sep 2024 //
BUSINESSWIRE
OrsoBio Presents Phase 1 and Preclinical Data at ADA 84th Sessions
21 Jun 2024 //
BUSINESSWIRE
Lilly backs OrsoBio`s $60M Series A for PhII trials in obesity and NASH
08 Nov 2023 //
ENDPTS
OrsoBio Announces $60M Series A Financing
07 Nov 2023 //
BUSINESSWIRE
OrsoBio to Present Phase 1 Data for Liver-Targeted LXR Inverse Agonist TLC-2716
06 Nov 2023 //
BUSINESSWIRE
OrsoBio to Present Phase 1 Data for the TLC-6740
16 Oct 2023 //
BUSINESSWIRE
OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial Protonophore
05 Jun 2023 //
BUSINESSWIRE
OrsoBio Announces First Patient Dosed in Phase 2 Trial of TLC-3595
20 Mar 2023 //
BUSINESSWIRE
OrsoBio Launches to Develop Novel Therapies for Severe Metabolic Disorders
01 Nov 2022 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.